Association of a HOXB13 variant with breast cancer

New England Journal of Medicine

Volumn 367, Issue 5, 2012, Pages 480-481

  Alanee, Shaheen ^a   Couch, Fergus ^b   Offit, Kenneth ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; BREAST CANCER; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMEOBOX; HOMEOBOX 13 GENE; HUMAN; LETTER; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WILD TYPE;

EID: 84864511887     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1205138     Document Type: Letter

References (4)

1. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012;366:141-9.
2. Cantile M, Pettinato G, Procino A, Feliciello I, Cindolo L, Cillo C. In vivo expression of the whole HOX gene network in human breast cancer. Eur J Cancer 2003;39:257-64. (Pubitemid 36057077)
3. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16. (Pubitemid 38748922)
4. Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjold B, Stal O. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res 2010;12:R53.